Supplementary Table 1: Summary of major clinical therapeutic studies utilizing interferon α-based therapies.

Author/Study Number of patients	Therapeutic Modalities	Treatment Duration	Baseline HDV Viral Load	Biochemical Outcome at EOT	Virologic Outcome at EOT	Serologic Outcome at EOT	SVR – 6 months post therapy follow-up
Farci P, et al.[99] N=42	IFN α-2a 3 or 9 MU TIW vs No Therapy	1 year	NR	ALT Normalization 4/14 (29%) – 3MU 10/14 (71%) – 9MU 1/13 (8%) – No Therapy	HDV RNA PCR negativity 5/14 (36%) – 3MU 10/14 (71%) – 9MU 0/13 (0%) – No Therapy	ALT Normalization + HDV RNA PCR Negativity 3/14 (21%) – 3MU 7/14 (50%) – 9 MU 0/13 (0%) – No Therapy	2/14 (14%) – 3MU 6/14 (43%) – 9MU 1/13 (8%) – No Therapy
Castelnau C, et al.[101] N=14	PegIFN α-2b 1.5 μg/kg/wk	1 year	$9x10^5$ copies/ml^	5/14 (36%) ALT normalization	8/14 (57%) Undetectable HDV RNA	1/14 (7%) lost HBsAg with seroconversion to anti-HBs	4/14 (29%) Undetectable HDV RNA
Niro GA, et al.[102] N=38	PegIFN α-2b 1.5 μg/kg/wk vs PegIFN α-2b 1.5 μg/kg/wk+RBV x48 wks then PegIFN α-2b for 24wks	72 weeks	NR	6/16 (37.5%) – PegIFN 9/22 (41%) – PegIFN + RBV	3/16 (19%) – PegIFN 2/22 (9%) – PegIFN + RBV	ALT normalization + HDV RNA PCR negativity in 20%	8/38 (21%) undetectable HDV RNA
Heller T, et	PegIFN α-2b	Up to 5	6.7 $\log_{10}$	6/12 (50%)	4/12 (30%)	3/12 (25%) with	NR

al.[103]	180 μg/week with increasing doses up to 360 μg/wk	years	GE/ml*	ALT normalization during therapy	with HDV RNA negativity	HDV RNA negativity and HBsAg loss	
Kabacam G, et al.[107] N=13	ETV 1mg/d	1 year	4.22 log_{10} copies/ml*	No change in ALT	No change in HDV RNA Undetected HDV RNA 3/13 (23%) patients	Increase in HBsAg titers (p=0.03)	NR
Lau DT, et al.[108] N=5	Lam 100mg/d	1 year	5.4 – 8.4 log_{10} copies/ml	No change in ALT	No change in HDV RNA	No change in HBsAg titers	N/A
Yurdaydin C, et al.[109] N=39	IFN 9MU TIW +/- Lam 100mg/d vs Lam 100mg/d	1 year	5 x 106 copies/ml^	9/14 (64%) IFN + Lam 5/8 (63%) IFN 3/17 (18%) Lam	7/14 (50%) IFN + Lam 4/8 (50%) IFN 2/17 (12%) Lam	NR	5/14 (36%) IFN + Lam 4/8 (50%) IFN 2/17 (12%) Lam
Wedemeyer H, et al.[110] HIDIT-1 N=90	PegIFN α-2a 180 μg ± ADV 10mg/d vs ADV 10 mg/d	1 year	6.3 log_{10} PegIFN + Adefovir^ 5.9 log_{10} PegIFN^ 5.7 log_{10} Adefovir^	10/31 (32%) PegIFN + Adefovir 8/29 (28%) PegIFN 2/30 (7%) Adefovir	7/31 (23%) PegIFN + Adefovir 7/29 (24%) PegIFN 0/30 (0%) Adefovir	HBsAg loss 2/31 (6%) PegIFN + Adefovir	8/31 (26%) PegIFN + Adefovir 9/29 (31%) PegIFN 0/30 (0%) Adefovir
Wedemeyer H, et al.[111]	PegIFN α-2a ± TDF 300mg/d	92 weeks	NR	NR	28/59 (48%) PegIFN + TDF	HBsAg loss 3/59 (5%) PegIFN	17/59 (29%) PegIFN + TDF

HIDIT-2 N=120					20/61 (33%) PegIFN	+ TDF 4/61 (6%) PegIFN	13/61 (21%) PegIFN

Symbols: *, Means; ^, median

Abbreviations: IFN, interferon; MU, million units; TIW, three times per week; NR, not reported; ALT, alanine aminotransferase; HDV, hepatitis D virus; EOT, end of treatment; SVR, sustained virological response; N, number; RNA, ribonucleic acid; PCR, polymerase chain reaction; PegIFN, Peginterferon; µg, microgram; kg, kilogram; wk, week; ml; milliliter; HBsAg, hepatitis B surface antigen; GE, genome equivalents; d, day; ETV, entecavir; LAM, lamivudine; ADV, adefovir; TDF, tenofovir; N/A, not applicable.